# US 2015/0148412 A1 · Polymorphs of darunavir

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0148412 A1
- Document ID: US20150148412A1
- Status: Published application
- Kind: A1
- Application number: 14/551,497
- Filed: 2014-11-24
- Published: 2015-05-28
- Earliest claimed: 2009-01-29
- Assignees: Mapi Pharma Ltd.
- Applicants: Mapi Pharma Limited
- Inventors: Ehud MAROM
- Web page: https://patentgrep.com/patent/US20150148412A1

## CPC

- C07D 493/04: Ortho-condensed systems
- A61K 9/20: Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)}
- A61K 31/34: having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/14: for RNA viruses
- A61P 31/18: for HIV
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- Y10T 428/2982: Particulate matter [e.g., sphere, flake, etc.]
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

The present invention provides new pseudopolymorphic forms of darunavir as well as a novel amorphous form of darunavir, pharmaceutical compositions comprising these compounds, methods for their preparation and use thereof in treating retroviral infections, in particular, HIV infection.

## Claims

### Claim 1

A process for preparing a solid amorphous form of darunavir characterized by an IR spectrum with characteristic peaks at about 1454 and 1369 cm−1, the process comprising the steps of:
(a) dissolving darunavir in CH2Cl2; and
(b) evaporating the CH2Cl2 until a precipitate is formed.

### Claim 2 (depends on 1)

The process according to claim 1, wherein the amorphous form of darunavir is characterized by an IR spectrum with characteristic peaks at about 1454, 1369, 771 and 553 cm−1.

### Claim 3

A solid crystalline dimethylsulfoxide solvate of darunavir having an X-ray powder diffraction pattern with diffraction peaks at 2-theta values of about 20.6±0.1 and 21.2±0.1.

### Claim 4 (depends on 3)

The crystalline dimethylsulfoxide solvate of darunavir according to claim 3, further characterized by an X-ray powder diffraction pattern with diffraction peaks at 2-theta values of about 20.6±0.1, 21.2±0.1, 16.6±0.1 and 23.0±0.1.

### Claim 5 (depends on 3)

The crystalline dimethylsulfoxide solvate of darunavir according to claim 3, further characterized by at least 3 X-ray diffraction peaks selected from about 7.1±0.1, 9.3±0.1, 10.6±0.1, 11.4±0.1, 13.9±0.1, 16.6±0.1, 17.3±0.1, 18.5±0.1, 20.1±0.1, 20.6±0.1, 21.2±0.1, 23.0±0.1, 27.1±0.1 and 28.1±0.1 degrees 2-theta.

### Claim 6 (depends on 3)

The crystalline dimethylsulfoxide solvate of darunavir according to claim 3, further characterized by an X-ray powder diffraction pattern with diffraction peaks at 2-theta values of about 7.1±0.1, 9.3±0.1, 10.6±0.1, 11.4±0.1, 13.9±0.1, 16.6±0.1, 17.3±0.1, 18.5±0.1, 20.1±0.1, 20.6±0.1, 21.2±0.1, 23.0±0.1, 27.1±0.1 and 28.1±0.1.

### Claim 7 (depends on 3)

The crystalline dimethylsulfoxide solvate of darunavir according to claim 3, which is in a micronized form.

### Claim 8 (depends on 7)

The crystalline dimethylsulfoxide solvate of darunavir according to claim 7, having a D90 particle size of less than about 9 μm.

### Claim 9 (depends on 8)

The crystalline dimethylsulfoxide solvate of darunavir according to claim 8, further having a D50 particle size of less than about 4 μm and a D10 particle size of less than about 2 μm.

### Claim 10 (depends on 3)

A solid pharmaceutical composition comprising as an active ingredient the crystalline dimethylsulfoxide solvate of darunavir according to claim 3, and a pharmaceutically acceptable carrier.

### Claim 11 (depends on 10)

The pharmaceutical composition according to claim 10 in the form of a tablet.

### Claim 12 (depends on 3)

A method of treating retroviral infections or inhibiting retrovirus protease activity comprising administering to a subject in need thereof an effective amount of a composition comprising the crystalline dimethylsulfoxide solvate of darunavir according to claim 3.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the retrovirus is HIV and wherein the subject is a human.

### Claim 14 (depends on 12)

The method according to claim 12, comprising co-administering the crystalline dimethylsulfoxide solvate of darunavir in combination with at least one other antiretroviral drug, wherein the at least one other antiretroviral drug is ritonavir.
